Changes in US stocks | Moderna (MRNA.US) rose nearly 5%, the results of the third phase of the melanoma study attracted attention

The Zhitong Finance App learned that on Wednesday, Moderna (MRNA.US) continued to rise at the beginning of the session and is now up nearly 5%, hitting a new high since August 19, with an increase of nearly 30% in the past two weeks. Since August 19, due to phase III clinical data catalyzed by mRNA cancer vaccine, the company's stock price has increased by more than 200% cumulatively. The market is currently paying close attention to the Phase III results of the Moderna study on adjuvant treatment of melanoma. The relevant data will be presented in the form of an updated summary at the European Society of Medical Oncology. The core indicator is survival time without recurrence.

UBS maintained a “neutral” rating on the stock until Moderna's key phase III melanoma trial data was released, with a target price of $150. According to UBS, the reason why this data release is important is because Moderna's stock price has risen markedly recently, and the market has taken into account quite a bit of positive expectations ahead of time.